NCT00119691

Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.

Conditions

• Congestive Heart Failure
• Renal Insufficiency

Interventions

Type	Name	Description
DRUG	Nesiritide	Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.

Timeline

• Start date: 2003-04-01
• Primary completion: 2005-11-01
• Completion: 2005-11-01
• First posted: 2005-07-14
• Last updated: 2013-09-12

Locations

1 site across 1 country: United States